PLK1 inhibition in cancer therapy: potentials and challenges

Future Med Chem. 2019 Jun;11(12):1383-1386. doi: 10.4155/fmc-2019-0084. Epub 2019 Jul 12.

Authors

Inas Elsayed^{1

2

3

4}, Xiaosheng Wang^{1

2

3}

Affiliations

¹ Biomedical Informatics Research Lab, School of Basic Medicine & Clinical Pharmacy, Nanjing 211198, PR China.
² Cancer Genomics Research Center, School of Basic Medicine & Clinical Pharmacy, Nanjing 211198, PR China.
³ Big Data Research Institute, China Pharmaceutical University, Nanjing 211198, PR China.
⁴ Department of Pharmacology, Faculty of Pharmacy, University of Gezira, Wad Madani 20, Sudan.

PMID: 31298578
DOI: 10.4155/fmc-2019-0084

No abstract available

Keywords: PLK1; PLK1 inhibitors; cancer therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Cell Cycle Proteins / antagonists & inhibitors*
Drug Design*
Humans
Neoplasms / drug therapy*
Neoplasms / metabolism
Polo-Like Kinase 1
Protein Kinase Inhibitors / pharmacology*
Protein Kinase Inhibitors / therapeutic use
Protein Serine-Threonine Kinases / antagonists & inhibitors*
Proto-Oncogene Proteins / antagonists & inhibitors*

Substances

Antineoplastic Agents
Cell Cycle Proteins
Protein Kinase Inhibitors
Proto-Oncogene Proteins
Protein Serine-Threonine Kinases